Gut

Parental obesity imprints offspring risk for MASLD: act now to protect future generations

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease, with the global prevalence rising from 25% to 38% in the past two decades.1 ...
Gut

Are the drugs already on the shelf? Repurposing therapy for pancreatitis

The persistent absence of disease-modifying therapy for recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) represents one of the more conspicuous therapeutic gaps in gastroenterology.
Gut

Impairment of Rab7-dependent STING degradation hampers HBV replication but accelerates disease progression in chronic hepatitis B comorbid with MASLD

Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
gut.bmj

The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease

1 Department of Gastroenterology, Hvidovre University Hospital, Faculty of Health Sciences, Copenhagen University, Hvidovre, Copenhagen, Denmark 2 Department of Internal Medicine, Copenhagen ...